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Abstract
Background: Tissue plasminogen activator (tPA) is known to have functions beyond fibrinolysis in acute ischemic 
stroke, such as blood brain barrier disruption. To further delineate tPA functions in the blood, we examined the gene 
expression profiles induced by tPA in a rat model of ischemic stroke.
Results: tPA differentially expressed 929 genes in the blood of rats (p ≤ 0.05, fold change ≥ |1.2|). Genes identified had 
functions related to modulation of immune cells. tPA gene expression was found to be dependent on the reperfusion 
status of cerebral vasculature. The majority of genes regulated by tPA were different from genes regulated by ischemic 
stroke.
Conclusions: tPA modulates gene expression in the blood of rats involving immune cells in a manner that is 
dependent on the status of vascular reperfusion. These non-fibrinolytic activities of tPA in the blood serve to better 
understand tPA-related complications.
Background
Tissue plasminogen activator (tPA) is currently the only
approved medical therapy for acute ischemic stroke. Its
use is limited to the first 3-4.5 hours after stroke onset
due to an increased risk of complications beyond this
time window such symptomatic hemorrhagic transfor-
mation (HT) [1]. Factors predisposing to tPA related HT
remain to be fully defined, though several features are
a s s o c i a t e d  w i t h  i n c r e a s e  H T  r i s k  i n c l u d i n g  t i m e  f r o m
stroke onset, hypo-attenuation on pretreatment CT, leu-
koaraiosis, NIHSS on admission, diabetes, high systolic
blood pressure, age, and thrombocytopenia [2,3]. tPA
acts by cleaving plasminogen into the active enzyme plas-
min, which degrades fibrin-based clots. The half-life of
tPA's proteolytic activity on plasminogen is 3-7 minutes.
In addition to tPA's fibrinolytic activity, a number of non-
fibrinolytic properties have been described for tPA, some
of which predispose to HT, blood brain barrier (BBB) dis-
ruption, and neuronal injury [4-7]. In this study, we
sought to better define tPA's effects in acute ischemic
stroke, determine if there is a blood gene expression pro-
file that correlates with tPA administration, and deter-
mine if this blood gene expression profile differs from the
profile associated with ischemic stroke.
Gene expression profiles are a useful tool to study com-
plex diseases, including ischemic stroke, as shown in pre-
vious studies of blood gene expression in humans and
animals [8-10]. The rationale for gene expression changes
in the blood following ischemic stroke is largely based on
the immune response to ischemic brain that is distinct
from other neurological conditions [11,12]. Gene expres-
s i o n  i s  a l s o  a f f e c t e d  b y  m e d i c a t i o n s ,  a s  o b s e rv e d  w i t h
aspirin in ischemic stroke and corticosteroids in Duch-
enne muscular dystrophy [8,13].
Using a rat model of ischemic stroke, we performed
gene expression analysis on whole blood samples to
determine the expression profile for tPA. A difference in
gene expression was observed between rats receiving tPA
c o m p a r e d  t o  r a t s  n o t  r e c e i v i n g  t P A .  S o m e  g e n e s
expressed following administration of tPA interacted
with ischemic stroke, with a different gene expression
profile for tPA in rats with middle cerebral artery occlu-
sion (MCAO) followed by reperfusion compared to rats
with permanent-MCAO. Despite the interaction between
tPA and ischemic stroke, the majority of the genes regu-
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lated by tPA can be distinguished from genes regulated by
ischemic stroke.
Results
There were no significant differences in physiologic
parameters between animals receiving tPA compared to
those not receiving tPA (data not shown). The median
neurological deficit score was 3 for both reperfused-
MCAO groups, with no significant difference between
rats treated with or without tPA (p = 0.32). The median
neurological deficit score was 3 for both permanent-
MCAO groups, with no significant different between rats
treated with or without tPA (p = 0.32).
Analysis 1. tPA and Ischemic stroke
Gene expression associated with tPA administration was
examined in an ANOVA model including tPA, ischemic
stroke, anesthesia, and the interaction between tPA and
ischemic stroke. tPA, ischemic stroke, and the interaction
between tPA and ischemic stroke were found to affect
gene expression.
tPA gene expression
There were 929 gene probes differentially regulated by
tPA (p ≤ 0.05, fold change ≥ |1.2|) (Additional File 1). Of
these 929 gene probes, 391 were up regulated (42.1%) and
538 were down regulated (57.9%). Functional analysis was
performed using IPA. The 929 gene probes mapped to
660 annotated genes and generated a total of 514 network
eligible genes. Among the top functions were cell signal-
ing, cellular assembly and organization, inflammatory
response, and cell death. Genes of interest include MMP9
(-1.84 fold), TLR2 (-1.38 fold), IL1R2 (-1.63 fold) and
CAMK4 (+1.35 fold) (Table 1-gene symbol abbrevia-
tions).
tPA and Ischemic Stroke
An interaction was identified between tPA and ischemic
stroke. There were 2332 gene probes regulated by isch-
emic stroke and 983 gene probes regulated by the interac-
tion of ischemic stroke with tPA (p ≤ 0.05, fold change ≥
|1.2|) (Figure 1). There were 130 genes regulated by isch-
emic stroke and tPA, 527 genes regulated by tPA and not
by ischemia, and 1944 genes regulated by ischemic stroke
that were not regulated by tPA (p ≤ 0.05, fold change ≥
|1.2|).
Analysis 2. tPA gene expression depends on the status of 
vascular reperfusion
tPA gene expression in rats with reperfused-MCAO
In rats with reperfused-MCAO, 533 genes probes were
differentially regulated by tPA at 24 hours (p ≤ 0.01, fold
change ≥ |1.2|) (Additional File 2). The 533 gene probes
comprised 193 up regulated (36.2%) and 340 down regu-
lated (63.9%) gene probes. Of these 533 gene probes, only
15 overlapped with gene probes expressed by tPA in rats
with permanent-MCAO (Figure 2). The 533 gene probes
clustered according to whether tPA was administered or
not (Figure 3a). Using the 533 gene probes as input to
Prediction Analysis of Microarrays (PAM), 27 gene
probes were found to optimally predict treatment with
tPA (Additional File 3). Ten-fold leave-one-out cross-vali-
dation showed that these probes were able to correctly
classify 12 of 12 rats based on treatment with tPA (Figure
3b).
Functional analysis was performed using IPA. The 533
gene probes mapped to 388 annotated genes and gener-
ated 316 network eligible genes. The top molecular func-
tional pathways relate to cell-cell signaling, cellular
organization and cell death (Table 2). These pathways
predominantly reflect activities of immune cells and their
interaction with endothelium. Top regulated genes
included MMP9 (-3.36 fold), SERPINB6 (-4.16 fold),
IL1R2 (2.14 fold), TLR2 (-1.69 fold), ICAM2 (-1.33), and
ANXA2 (-1.21 fold).
tPA gene expression in rats with permanent-MCAO
In rats with permanent-MCAO, treatment with tPA led
to differential regulation of 293 gene probes at 24 hours
(p ≤ 0.01, fold change ≥ |1.2|) (Figure 2) (Additional File
4). Of the 293 gene probes, 170 were up regulated (58.0%)
and 123 were down regulated (42.0%). The 293 gene
probes clustered by tPA administration (Figure 4a). Using
the 293 gene probes as input to PAM, 62 probes were
found to optimally predict treatment with tPA (Addi-
tional File 5). Ten-fold leave-one-out cross-validation
showed that these gene probes were able to correctly clas-
sify 12 of 12 rats based on treatment with tPA (Figure 4b).
Functional analysis was performed using IPA. The 293
gene probes mapped to 181 annotated genes and gener-
ated 142 network eligible genes. The top molecular func-
tional pathways were cell-to-cell signaling, cellular
movement, and cellular organization (Table 2). These
pathways predominantly reflect activities of immune cells
and their interaction with endothelium. Top regulated
genes include TIMP3 (+2.39 fold), ITGB2 (+1.21 fold),
COL17A1 (+1.27 fold), GZMB (+1.74 fold), JAG1 (-2.09
fold), CSF-1 (-1.70 fold), SLP1 (-1.70 fold), FCGR2B (-
1.51 fold), and PIK3CD (-1.31 fold).
Discussion
tPA administration was associated with differential
expression of 929 gene probes in the blood of rats with
ischemic stroke. The genes expressed by tPA differed
depending on whether or not ischemic stroke was accom-
panied by reperfusion. Most genes had functions related
to modulation of immune cells. This data is important as
it has potential implications for tPA treatment of isch-
emic stroke and understanding the pharmacogenomics of
tPA.Jickling et al. BMC Genomics 2010, 11:254
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Table 1: List of gene symbol abbreviations.
Gene Symbol Entrez Gene Name Gene Symbol Entrez Gene Name
ANXA1 annexin A1 ITGB2 integrin, beta 2 (complement 
component 3 receptor 3 and 4 
subunit)
ANXA2 annexin A2 JAG1 jagged 1 (Alagille syndrome)
BCL6 B-cell CLL/lymphoma 6 LY96 lymphocyte antigen 96
CAMK4 calcium/calmodulin-
dependent protein kinase IV
ORAI1 ORAI calcium release-activated 
calcium modulator 1
COL17A1 collagen, type XVII, alpha 1 PIK3CD phosphoinositide-3-kinase, 
catalytic, delta polypeptide
CSF1 colony stimulating factor 1 
(macrophage)
TIMP3 TIMP metallopeptidase 
inhibitor 3
F5 coagulation factor V 
(proaccelerin, labile factor)
TLR2 toll-like receptor 2
FCGR2B Fc fragment of IgG, low affinity 
IIb, receptor (CD32)
XDH xanthine dehydrogenase
FGR Gardner-Rasheed feline 
sarcoma viral (v-fgr) oncogene 
homolog
MMP9 matrix metallopeptidase 9 
(gelatinase B, 92kDa 
gelatinase, 92kDa type IV 
collagenase)
GZMB granzyme B (granzyme 2, 
cytotoxic T-lymphocyte-
associated serine esterase 1)
SELL selectin L
ICAM2 intercellular adhesion 
molecule 2
SERPINB6 serpin peptidase inhibitor, 
clade B (ovalbumin), member 6
IL1R2 interleukin 1 receptor, type II SLPI secretory leukocyte peptidase 
inhibitor
tPA and the Immune System
tPA modulated gene expression related to the immune
system. This is not unexpected, given that immune cells
are intimately involved in tPA related complications of
BBB breakdown and HT of ischemic brain tissue [5].
Moreover, tPA has previously been reported to act on a
number of immune cells, including mast cells and neutro-
phils.
Mast cells play various roles in ischemic stroke, includ-
ing altering BBB permeability, hemorrhage formation,
brain edema formation, and regulation of local neutrophil
infiltration [14]. tPA promotes mast cell degranulation,
thus enhancing release of vasoactive, proteolytic, and
fibrinolytic substances. Mast cell stabilization with cro-
moglycate reduces tPA related brain hemorrhage, brain
edema and neutrophil infiltration [15]. In our study, we
identified a number of genes differentially regulated by
tPA that affect mast cells, including those involved in
mast cell activation (FCGR2B) and mast cell degranula-
tion (COL17A, PIK3CD, ORAI1).
Neutrophils are recruited and activated early on follow-
ing ischemic stroke. tPA has been shown to promote neu-
trophil degranulation [16,17]. Upon degranulation,
neutrophils release preformed granules containing prote-Jickling et al. BMC Genomics 2010, 11:254
http://www.biomedcentral.com/1471-2164/11/254
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olytic enzymes, including matrix metalloproteinase-9
(MMP-9), that facilitate migration of leukocytes across
the BBB to ischemic brain tissue [18]. The mechanisms
by which tPA acts on neutrophils to mediate these effects
are unknown. However, products of tPA clot degradation
may contribute in part to neutrophil activation and infil-
tration [19]. A number of the identified tPA regulated
genes in our study are associated with neutrophils. In the
reperfused-MCAO group, tPA was associated with genes
involved in neutrophil activation (SELL, ANXA1, SLPI)
and neutrophil migration (MMP9, FGR, FCGR2B). In the
permanent-MCAO group, genes involved in neutrophil
attachment to endothelium (ITGB2) and genes involved
in neutrophil recruitment (SLP1, CSF-1) was observed.
Further study is required to delineate the effects of tPA on
immune response in ischemic stroke, including determi-
nation of the specific immune cells and pathways affected
by tPA. These potentially identify new targets to reduce
tPA related complications in ischemic stroke and perhaps
extend the therapeutic window of tPA.
tPA and Immune-Endothelial Effects
Endothelial cells form an integral part of the BBB along
with the basal lamina and astrocytic foot processes. tPA
can affect endothelial cells in both a direct and indirect
manner. Indirectly tPA modulates immune cells that
interact with endothelium. tPA increases endothelial
adhesion molecule expression including ICAM2, P-Selec-
tin, and E-Selectin [20,21]. Direct effects of tPA on
endothelial cells is mediated via the Lipoprotein Receptor
Protein-1 (LRP-1). Binding of tPA to LRP-1 initiates a sig-
nal cascade that up regulates endothelial MMP-9 and dis-
rupts the BBB [22-24].
Our study identified a number of differentially regu-
lated genes involved in immune-endothelial signaling
pathways, including genes involved in inflammatory cell
adhesion, migration, and recruitment. In the reperfused-
MCAO group, genes involved in immune-endothelial
interaction include ICAM2, CEACAM1, ID1, and
ACTN1. Notably, genes involved in immune-endothelial
signaling were not as significantly affected by tPA in the
permanent-MCAO group. This suggests that further
study of genes involved in immune-endothelial interac-
tion may provide insight into the increased risk of tPA
related HT in subjects with reperfusion compared to per-
manent occlusion.
tPA and MMP-9
MMP-9 has been studied in ischemic stroke at both the
protein and RNA level in blood and brain. MMP-9 is a
protease that degrades extracellular matrix and promotes
BBB breakdown. Protein levels of MMP-9 increase in the
blood early on after ischemic stroke onset, and this
increase is enhanced by tPA [25,26]. In rats treated with
tPA, the rise in blood MMP-9 peaks by 6 hours and
return to baseline by 24 hours [25]. In human stroke
patients treated with tPA, a similar rise blood MMP-9
occurs by 8 hours and with a return to baseline by 25
hours [26]. MMP-9 mRNA expression in the blood fol-
lowing tPA treated ischemic stroke remains poorly stud-
ied. We found MMP-9 mRNA to be reduced at 24 hours.
This is consistent with an early rise of MMP-9 levels in
the blood by 6-8 hours, followed by a reduction by 24
h o u r s .  T h i s  i s  i n  c o n t r a s t  t o  t h e  p a t t e r n  o f  M M P - 9
expression in the brain, where levels remain elevated at
the 24-30 hour time point [27,28]. Further study is
required to better delineate MMP-9 mRNA expression
patterns in blood, including the relationship with vascu-
lar reperfusion, duration of cerebral ischemia, treatment
with tPA, and correlation with expression patterns of
MMP-9 in cerebral tissue.
Figure 1 Venn diagram of numbers of gene probes differentially 
regulated by tPA, ischemic stroke, and tPA-ischemic stroke inter-
action from the ANOVA analysis (p ≤ 0.05, fold change ≥ |1.2|).
Figure 2 Venn diagram of gene probes differentially regulated 
by tPA in rats with a 2 hour MCAO followed by 22 hours of reper-
fusion (Reperfused-MCAO) and rats with permanent 24 hour 
MCAO without reperfusion (Permanent-MCAO) (p < 0.01, fold 
change of ≥ |1.2|. (MCAO = middle cerebral artery occlusion)Jickling et al. BMC Genomics 2010, 11:254
http://www.biomedcentral.com/1471-2164/11/254
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tPA and Cerebral Reperfusion
The genes regulated by tPA in the blood were different
depending on the status of vascular reperfusion. Rats rep-
erfused after two hours of cerebral ischemia had a differ-
ent tPA gene expression profile than rats with
permanent-MCAO. Reperfusion of ischemic vasculature
and cerebral tissue leads to cerebral ischemia/reperfusion
(IR) injury. This injury includes glutamate-mediated exci-
totoxicity, oxidative stress, inflammation, and necrotic or
apoptotic cell death [29]. Our study suggests that tPA
modulates IR injury beyond the effects mediated by rep-
erfusion alone. This modulation includes alteration of
immune cells and immune-endothelial interaction. I/R
injury is a complex process and its impact on clinical out-
come in ischemic stroke is dependent on numerous fac-
tors including intensity and duration of ischemic insult,
time to reperfusion, and the microcirculation [30]. Fur-
ther study of tPA's effects on reperfusion may aid in iden-
tifying targets to reduce the contribution of tPA to I/R
injury.
tPA and Ischemic stroke
Blood gene expression profiling is a promising approach
for diagnosing and understanding the pathogenesis of
ischemic stroke [8,9]. In this study of rat ischemic stroke
we were able to identify a gene expression profile associ-
ated with rat ischemic stroke. Some of the ischemic
stroke genes were also regulated by tPA, indicating an
interaction between ischemic stroke and tPA. However,
m a n y  g e n e s  a s s o c i a t e d  w i t h  i s c h e m i c  s t r o k e  a r e  n o t
affected by tPA including BCL6, F5, and LY96 which were
previously found to be predictive of ischemic stroke in
humans [8]. Of the 1355 genes previously identified in
humans to be differentially regulated by ischemic stroke,
only 79 overlapped with the 929 tPA genes we identified
in this study of rats [8]. This suggests that although tPA
affects the gene expression profile in whole blood and
should be considered when evaluating gene expression
profiles in acute ischemic stroke, it is possible to distin-
guish tPA effects from the effects of ischemic stroke on
gene expression. A gene expression profile can also be
u sed  t o  i d e n t i fy  e x pos u r e  t o  d ru g  t r ea t m e n t.  W e  w e r e
able to correctly predict tPA use in 12 out 12 rats with 27
gene probes in the reperfused-MCAO group and 62 gene
probes in the permanent-MCAO group.
A strength of our study is the measurement of all
known genes in the blood to determine those altered by
tPA in ischemic stroke. A limitation is the analysis of
b l o o d  g e n e  e x p r e s s i o n  o n l y .  t P A  i s  k n o w n  t o  m e d i a t e
effects on endothelium and brain, thus further study is
required to correlate changes in the blood with changes
in these tissues. Additionally, we were only able to investi-
gate a single dosage of tP A at a single time point. The
equivalent dose for non-fibrinolytic effects of tPA in rats
Figure 3 Analysis of gene probes differentially regulated in the blood of rats with reperfused-MCAO (p ≤ 0.01, fold change ≥ |1.2|). (3a) Hi-
erarchical cluster plot showing gene probes clustering by treatment with tPA. (3b) Cross-validation with Prediction Analysis of Microarrays (PAM) of 
gene probes differentially regulated by tPA. The 27 gene probes correctly predict treatment with tPA. (Rats not treated with tPA are shown on the x-
axis by numbers 1-6, rats treated with tPA are number 7-12; y-axis represents the cross-validated probability of the predicted class)Jickling et al. BMC Genomics 2010, 11:254
http://www.biomedcentral.com/1471-2164/11/254
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Table 2: List of top 5 networks, canonical pathways and molecular functional pathways, for gene differentially regulated 
by tPA in the reperfused-MCAO group and permanent-MCAO group (p ≤ 0.01, fold change ≥ |1.2|).
Reperfused-MCAO Permanent-MCAO
Network IPA Score Network IPA Score
1 Carbohydrate Metabolism, 
Lipid Metabolism, Small 
Molecule Biochemistry
43 Gene Expression, Cell 
Cycle, Lipid Metabolism
41
2 Organismal Survival, 
Connective Tissue 
Development and 
Function, Tissue 
Development
43 Cellular Assembly and 
Organization, Cellular 
Function and 
Maintenance, Cancer
34
3 Lipid Metabolism, 
Molecular Transport, Small 
Molecule Biochemistry
39 Genetic Disorder, 
Metabolic Disease, 
Neurological Disease
25
4 Inflammatory Response, 
Connective Tissue 
Disorders, Inflammatory 
Disease
34 Cellular Compromise, Drug 
Metabolism, Endocrine 
System Development and 
Function
25
5 Cellular Compromise, Cell 
Morphology, Endocrine 
System Development and 
Function
22 DNA Replication, 
Recombination, and 
Repair, Cancer, Cell Cycle
22
Canonical Pathway P-value Canonical Pathway P-value
1 Nicotinate and 
Nicotinamide Metabolism
3.27E-04 FcgRIIB Signaling in B 
Lymphocytes
1.01E-02
2 Hypoxia Signaling in the 
Cardiovascular System
8.48E-04 p38 MAPK Signaling 1.89E-02
3 Role of NFAT in Regulation 
of the Immune Response
4.77E-03 Glucocorticoid Receptor 
Signaling
2.33E-02
4 B Cell Receptor Signaling 1.72E-02 Estrogen Receptor 
Signaling
3.09E-02
5 TREM1 Signaling 1.97E-02 Macropinocytosis 3.86E-02
Molecular Functional 
Pathway
P-value Molecular Functional 
Pathway
P-value
1 Cell-To-Cell Signaling and 
Interaction
7.10E-04 - 4.50E-02 Gene Expression 1.65E-04 - 1.29E-02Jickling et al. BMC Genomics 2010, 11:254
http://www.biomedcentral.com/1471-2164/11/254
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compared to humans remains unknown, therefore results
need to be interpreted with this in mind. Finally, anesthe-
sia was used in the experimental model. Although
accounted for in the ANOVA model, anesthesia may still
have had some effect on gene expression.
Conclusions
A gene expression profile for tPA was identified in our rat
model of ischemic stroke. The changes of gene expression
by tPA reflect modulation of the immune cells. The pat-
terns of gene expression by tPA were dependent on the
status of cerebrovascular reperfusion. The majority of
genes modulated by tPA in blood are distinct from those
modulated by ischemic stroke. This suggests that in the
blood of humans it should be possible to monitor gene
expression profiles that correspond both to ischemic
stroke and to the pharmacological effects of tPA.
Methods
1. Animals
Forty-two male Sprague-Dawley rats weighing 280-350
grams (Charles River Labs, USA) were used in this study
with a mean age of 2.4 months. The University of Califor-
nia at Davis Animal Care Committee approved the ani-
mal protocol in accordance with NIH guidelines. Animals
were randomly assigned to one of seven experimental
groups (n = 6 per group, N = 42 total): (1) Naïve; (2)
Anesthesia; (3) tPA at 3 hours with no MCAO; (4) Reper-
fused-MCAO (2 hours of MCAO followed by 22 hours of
reperfusion); (5) Reperfused-MCAO + tPA at 3 hours (6)
Permanent-MCAO (24 hours MCAO with no reperfu-
sion); and (7) Permanent-MCAO + tPA at 3 hours. Neu-
rologic examinations were performed at 4 and 24 hours.
T h e  n e u r o l o g i c  f i n d i n g s  w e r e  s c o r e d  o n  a  f o u r - p o i n t
scale: 0, no neurologic deficit; 1, right Horner's syn-
drome; 2, failure to extend left forepaw fully; 3, circling to
the left [31].
2. Focal ischemia
MCAO was produced using the intraluminal suture tech-
nique [31]. Rats were anesthetized with 3% isoflurane and
maintained on 1.5% isoflurane in 100% oxygen. The right
common carotid artery was exposed, and a 3-0 monofila-
ment nylon suture was inserted into the external carotid
artery and advanced into the internal carotid artery 20-23
mm beyond the carotid bifurcation until resistance was
felt. MCAO was maintained for 2 hours in the reper-
fused-MCAO group and 24 hours in the permanent-
MCAO group. Reperfusion was achieved by withdrawing
the suture at 2 hours after MCAO onset. A heating blan-
ket was used to maintain rectal temperature at 36.5°C to
37.5°C. Three hours following ischemia onset, tPA (3.3
mg/kg IP) was administered to rats in the tPA treatment
groups. This dose of tPA is within the range of previous
studies on rats of 3-10 mg/kg [32,33]. We opted for a dose
of tPA on the lower end of this range to be more compa-
rable to the dose used in rabbits and humans in the study
of tPA's non-fibrinolytic effects. Recombinant human tPA
used was a gift from Genentech Inc. (South San Fran-
cisco, CA). Animals were anesthetized with 3% isoflurane
at 24 hours, and a blood sample drawn.
3. Sample processing and microarray hybridization
Blood was collected into PAXgene vacutainer tubes via
cardiac puncture (PreAnalytiX, Germany). RNA was iso-
lated using the PAXgene blood RNA kit (PreAnalytiX,
Germany). Reverse transcription, amplification, and sam-
ple labeling were carried out using Nugen's Ovation
Whole Blood reagents (Nugen Technologies, San Carlos,
C A ) .  E a c h  R N A  s a m p l e  w a s  h y b r i d i z e d  a n d  s c a n n e d
according to the manufacturer's protocol onto Affyme-
trix Rat Genome 230 2.0 GeneChips (Affymetrix Santa
Clara, CA). The arrays were washed and processed on a
Fluidics Station 450 and scanned on a Genechip Scanner
3000. Microarray data have been deposited in the NCBI
2 Cellular Assembly and 
Organization
7.10E-04 - 3.47E-02 Cell-To-Cell Signaling and 
Interaction
6.52E-04 - 4.37E-02
3 Cell Cycle 1.40E-03 - 3.93E-02 Cellular Movement 8.51E-04 - 4.56E-02
4 Cellular Function and 
Maintenance
1.97E-03 - 3.33E-02 Carbohydrate Metabolism 1.61E-03 - 3.81E-02
5 Cell death/Survival 2.09E-03 - 2.85E-02 Cellular Assembly and 
Organization
2.03E-03 - 4.69E-02
Key: The majority of the pathways identified reflect activities of immune cells and their interaction with endothelium. (IPA, Ingenuity Pathway 
Analysis; MCAO, middle cerebral artery occlusion; tPA, tissue plasminogen activator)
Table 2: List of top 5 networks, canonical pathways and molecular functional pathways, for gene differentially regulated 
by tPA in the reperfused-MCAO group and permanent-MCAO group (p ≤ 0.01, fold change ≥ |1.2|). (Continued)Jickling et al. BMC Genomics 2010, 11:254
http://www.biomedcentral.com/1471-2164/11/254
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Gene Expression Omnibus (GEO) database Accession
Number GSE21136.
4. Probe-level data analysis
Raw expression values (probe level data) were imported
into Partek software (Partek Inc., St. Louis, MO) and pro-
cessed using GC-RMA normalization [34]. Statistical
analysis, principal components analysis, and hierarchical
u n s u p e r v i s e d  c l u s t e r i n g  a n a l y s i s  w e r e  p e r f o r m e d  w i t h
Partek Genomics Suite 6.04. Probe lists were analyzed
using PAM (Prediction Analyses of Microarrays) nearest
shrunken centroids to identify the minimum number of
gene probes able to differentiate specified groups [35].
PAM analysis uses a 10-fold leave-one-out cross-valida-
tion, meaning the model is fit to 90% of the samples and
the class of the remaining 10% of samples are predicted.
This procedure is repeated 10 times to compute the over-
all error in the model. Ingenuity Pathway Analysis (IPA,
Ingenuity Systems®, http://www.ingenuity.com) was used
to determine whether the numbers of genes regulated
within given pathways or cell functions were greater than
expected by chance.
5. Statistical analyses
To evaluate gene expression differences related to tPA,
two analyses were performed. The first analysis was
designed to identify gene expression associated with tPA
administration and determine the relationship between
tPA and ischemic stroke on gene expression. Using analy-
sis of variance (ANOVA) the effects of tPA, ischemic
stroke, anesthesia, and the interaction of tPA*ischemic
stroke were evaluated. Unsupervised hierarchical cluster-
ing and principal components analysis were used to eval-
uate relationships between tPA treated and non-tPA
treated rats. Gene probes with a p value ≤ 0.05 and a fold
change ≥ |1.2| were considered significant.
The second analysis was designed to examine the genes
regulated by tPA in rats as a function of reperfusion sta-
tus. ANOVA was performed comparing tPA treated rats
to non-tPA treated rats in the reperfused-MCAO groups.
Similarly, ANOVA was performed comparing tPA treated
rats to non-tPA treated rats in the permanent-MCAO
groups. Given the smaller sample size relative to analysis
1, gene probes with a p value ≤ 0.01 and a fold change ≥
|1.2| were considered significant. Student's t tests were
performed to determine differences between tPA treated
and non-treated groups. The Mann-Whitney rank sum
test was performed for analysis of neurological score. All
data are presented as mean ± SE.
Additional material
Additional file 1 List of genes regulated by tPA in rat ischemic stroke. 
The 929 gene probes differentially regulated by tPA in rats with ischemic 
stroke (p ≤ 0.05, fold change ≥ |1.2|.
Additional file 2 List of genes regulated by tPA in reperfused-MCAO. 
The 533 genes probes differentially regulated by tPA at 24 hours in rats with 
reperfused-MCAO, (p ≤ 0.01, fold change ≥ |1.2|).
Figure 4 Analysis of gene probes differentially regulated in the blood of rats with permanent-MCAO without reperfusion (p ≤ 0.01, fold 
change ≥ |1.2|). (4a) Hierarchical cluster plot showing gene probes clustering by treatment with tPA. (4b) Cross-validation with Prediction Analysis of 
Microarrays (PAM) of gene probes differentially regulated by tPA. The 62 gene probes correctly predict treatment with tPA. (Rats not treated with tPA 
are shown on the x-axis by numbers 1-6, rats treated with tPA are number 7-12; y-axis represents the cross-validated probability of the predicted class)Jickling et al. BMC Genomics 2010, 11:254
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